Стан клітинного імунітету хворих на тонзиліт дітей, інфікованих вірусом герпеса 6 типу

Abstract

Currently, the incidence of tonsillitis in children is very common and represents a serious medical and social problem. In young children, viral tonsillitis predominates, while bacterial tonsillitis is more common between the ages of 5–15. The frequency of registration of infection with viruses of the herpes group, including the human herpes virus (HHV) type 6, is increasing. The healing processes in infectious pathology are primarily due to the balanced work of the cellular and humoral links of the body’s immune response, the state of which can be influenced by concomitant infection with herpes viruses. The aim of the work was to study the cellular immune response of children with tonsillitis infected with HHV-6 type. The study of the influence of HHV-6 infection on the state of the cellular component of the immune response in 74 children with tonsillitis in the acute period and in the period of convalescence was carried out. All patients were diagnosed with a moderate form of tonsillitis; the etiological factor was hemolytic streptococcus group A. It was revealed that in children with mono-infection at the onset of the disease, there is a moderate response of cellular immunity (t = 2.76), while the presence of HHV-6 infection leads to more pronounced changes in the parameters of CD lymphocytes (t = 4.06). We found a significant increase in the content of CD16+-lymphocytes in tonsillitis of streptococcal etiology, but the maximum growth was recorded in patients with mono-infection (p < 0.05). By the time of convalescence, complete recovery of T-lymphocytes in infected HHV-6 patients does not occur. The degree of deviation from the standard for the entire complex of CD-lymphocytes during the period of convalescence was more pronounced in patients with co-infection (t = 2.83). The obtained data indicate the suppression of the cellular component of the immune response in patients with tonsillitis against the background of HHV-6 infection, which requires a differentiated approach to treatment and medical supervision of such patients.